JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

JNJ

225.57

+0.63%↑

UNH

363.82

-1.87%↓

TMO

466.62

+0.92%↑

ISRG

451.55

-0.21%↓

ABT

87.15

-0.47%↓

Home・Akcijų sąrašas・Sana Biotechnology Inc

Sana Biotechnology Inc

Uždarymo kaina

SektoriusSveikatos priežiūra

3.27 -0.91

Pirkti Parduoti

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

3.27

Max

3.31

Pagrindiniai rodikliai
By Trading Economics
Pajamos	-17M -59M
Darbuotojai	142
EBITDA	-19M -58M

Rekomendacijos
By TipRanks
Rekomendacijos	Stiprus pirkimas
12 mėnesių prognozė	+145.87% upside

Dividendai
By Dow Jones
Kitas uždarbis	2026-05-06

Rinkos statistika
By TradingEconomics
Rinkos kapitalizacija	-185M 921M
Ankstesnė atidarymo kaina	4.18
Ankstesnė uždarymo kaina	3.27

Naujienos nuotaikos

By Acuity

50%

180 / 347 reitingas Healthcare

Techninis įvertinimas

By Trading Central

Pasitikėjimas

Strong Bullish Evidence

1.68 / 1.87 Palaikymas ir pasipriešinimas

Sana Biotechnology Inc Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2026-05-05 23:43; UTC

Svarbiausios naujienos

New Zealand's Unemployment Rate Falls in 1Q

2026-05-05 23:20; UTC

Karštos akcijos

Stocks to Watch: AMD, Super Micro, Arista Networks, Freshworks

2026-05-05 21:48; UTC

Uždarbis

Suncor Energy Reports Higher 1Q Profit on Increased Oil Production

2026-05-05 21:05; UTC

Įsigijimai, susijungimai, perėmimai

Canada Antitrust Watchdog Seeks to Kibosh Keyera Deal for Plains' Canada Gas Business -- 4th Update

2026-05-06 00:00; UTC

Rinkos pokalbiai

Canada Energy Minister Signals Energy Investments in the Pipeline -- Market Talk

2026-05-05 23:39; UTC

Rinkos pokalbiai

Gold Rises; Trump Pauses 'Project Freedom' to See if Iran Deal Can Be Finalized -- Market Talk

2026-05-05 22:26; UTC

Rinkos pokalbiai

AMD Data-Center Business Continues to Surge -- Market Talk

2026-05-05 22:20; UTC

Rinkos pokalbiai

AMD's AI Revolution is Still in Early Innings, Analysts Say -- Market Talk

2026-05-05 22:08; UTC

Uždarbis

Correction to "Palantir Beats Forecasts" on May 4. -- WSJ

2026-05-05 22:07; UTC

Uždarbis

AMD Stock Soars on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Adj EPS $1.09 >PAAS

2026-05-05 21:48; UTC

Uždarbis

Pan American Silver 1Q Rev $1.2B >PAAS

2026-05-05 21:42; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:38; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:30; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:29; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:26; UTC

Uždarbis

Strategy Posts Wider Loss as Bitcoin Holdings Hit $64 Billion. The Stock Falls. -- Barrons.com

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q EPS 39c >ALC.EB

2026-05-05 21:25; UTC

Uždarbis

Alcon Inc. 1Q Rev $2.71B >ALC.EB

2026-05-05 21:24; UTC

Uždarbis

AMD Stock Jumps on Strong Earnings and Growing Confidence About AI -- Barrons.com

2026-05-05 21:18; UTC

Uždarbis

Mistras Backs 2026 Rev $730M-$750M >MG

2026-05-05 21:17; UTC

Uždarbis

AMD Stock Jumps on Solid Earnings. AI Continues to Drive Data Center Chips. -- Barrons.com

2026-05-05 21:15; UTC

Uždarbis

Strategy Records Loss of Nearly $13 Billion as Bitcoin Continues Decline -- WSJ

2026-05-05 21:12; UTC

Uždarbis

These Stocks Are Today's Movers: Intel, PayPal, Palantir, Shopify, Micron, Duolingo, and More -- Barrons.com

2026-05-05 21:11; UTC

Uždarbis

SSR Mining 1Q Rev $581.8M >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q Adj EPS $1.15 >SSRM

2026-05-05 21:10; UTC

Uždarbis

SSR Mining 1Q EPS $1.16 >SSRM

2026-05-05 21:08; UTC

Uždarbis

Arista Networks Beats Expectations, Offers Upside Guidance. The Stock Is Down. -- Barrons.com

2026-05-05 21:01; UTC

Uždarbis

Intact Financial 1Q EPS C$4.12 >IFC.T

2026-05-05 21:01; UTC

Karštos akcijos

Stocks to Watch Recap: Palantir, AMD, Intel, HSBC -- WSJ

Akcijų palyginimas

Kainos pokytis

Sana Biotechnology Inc Prognozė

Kainos tikslas

By TipRanks

145.87% į viršų

12 mėnesių prognozė

Vidutinis 8.04 USD 145.87%

Aukščiausias 12 USD

Žemiausias 3.21 USD

Remiantis 6 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines Sana Biotechnology Inc kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Stiprus pirkimas

6 ratings

Pirkti

Laikyti

Parduoti

Remiantis 6 analitikų, pateikusių Sana Biotechnology Inc akcijų reitingus – Dist per pastaruosius 3 mėnesius.

Techninis įvertinimas

By Trading Central

1.68 / 1.87Palaikymas ir pasipriešinimas

Recent bullish events outweigh bearish events.

Recent bearish events outweigh bullish events.

There are no events.

Rinkos nuotaikos

By Acuity

180 / 347 reitingas Sveikatos priežiūra

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

Apie bendrovę Sana Biotechnology Inc

Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.